
Opinion|Videos|April 11, 2025
PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
Panelists discuss how PSMA PET imaging plays a crucial role in the initial staging of prostate cancer, offering superior accuracy over conventional methods. Medical professionals consider factors such as diagnostic performance, tracer availability, and patient-specific characteristics when selecting appropriate PSMA PET agents. The integration of PSMA PET findings into clinical practice has led to more precise treatment planning, potentially improving patient outcomes. Pivotal trials have demonstrated the efficacy of various PSMA PET tracers in detecting prostate cancer metastases.
Advertisement
Episodes in this series

- Video content above is prompted by the following: Briefly discuss the role of PSMA PET imaging for initial disease staging for patients with prostate cancer, considerations for selecting PSMA PET imaging agents, and how imaging guides treatment decisions in this setting.
- What percentage of your newly diagnosed patients receive PSMA PET imaging, and what is your typical approach when using it in this setting?
- How does PSMA PET imaging guide initial disease staging?
- What do available data from pivotal trials demonstrate, and how do these findings influence your decisions in this setting?
- PSMA-PreRP – Illuccix (gallium Ga68 gozetotide) Hope et al. JAMA. 2021
- OSPREY – Pylarify (piflufolastat F18) Pienta et al. J Urol. 2021
- LIGHTHOUSE – Posluma (flotufolastat F18) Surasi et al. Eur Urol. 2023
Advertisement
Related to this article

Testosterone therapy was not associated with disease progression in a retrospective 3324-patient active surveillance prostate cancer cohort.

In the phase 2 TRAP trial, the median PFS after SBRT was 3.0 months with detectable ctDNA vs 7.8 months without it in oligoprogressive CRPC.

At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.

The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.

Martin Gleave, CM, MD, FRCSC, FACS, discussed perioperative therapy selection, the GUNS trial, and postoperative radiotherapy in prostate cancer.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

The ACS now recommends biennial PSA screening for average-risk men aged 50 to 69 years and annual screening from age 45 for Black men.
Advertisement
Advertisement
Trending on CancerNetwork
1
A New Era of Personalized Cancer Therapeutics at ESMO
2
BELLWAVE Program for Nemtabrutinib Discontinued After Phase 3 CLL/SLL Trial
3
FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers
4
ET Adherence Raises Cardiometabolic Risk, Improves Survival in HR+ Breast Cancer
5

